Sai Parenterals Q1 FY27 - Rs 182cr revenue, new acquisitions, EBOS contract AUD 202mn

Q1 FY27 consolidated revenue Rs 182 crores, gross margin improved to 41.8% from 38.1% (+370 bps), EBITDA Rs 27 crores at 14.9%. Full year FY27 guidance maintained at Rs 750 crores revenue at around 17% EBITDA margin. Board approved redeployment of Rs 101.85 cr IPO funds: Rs 83.83 cr for 60% stake in Saicriti Pharma (new EU-GMP and USFDA injectable facility delivering 47% more capacity, completion April 2027) and Rs 15 cr for 60% in Prathyak Labs (R&D with 150 SKUs and 28 scientists). EBOS Group contract renewed at AUD 202 million for 7.5 years. Debt Rs 310 cr, de-leveraging expected from FY28.